RxDoctor Payments Data

James Rini, MD

Neurology · Mobile, ALNPI 1104211903

Payments from drug & device makers

$960in general payments, 2019–2025

Across 34 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$158
  • Eisai Inc.$148
  • Sunovion Pharmaceuticals Inc.$121
  • Novartis$116
  • Biogen$112
  • Teva Pharmaceuticals USA, Inc.$85
  • plus $219 from 6 others

What the payments were for

  • Speaking & faculty fees$374%
  • Food & beverage$92396%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$960 in reported general payments places this provider in the 35th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$80,709
Medicare patients
185
Services billed
838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant386$177,082
GemtesaVibegron33$16,003
MyrbetriqMirabegron17$10,484
LinzessLinaclotide17$9,027
Memantine Hcl245$8,395
Rivastigmine42$5,992
Donepezil Hcl427$3,386
Quetiapine Fumarate97$1,578
Clonazepam106$1,510
Divalproex Sodium49$1,303
Modafinil40$1,252
Carbidopa-LevodopaCarbidopa/Levodopa75$1,084
Ramelteon14$973
Levetiracetam69$817
Lamotrigine89$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$59$9,02717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 255 neurology providers in Alabama.

Other neurology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →